Literature DB >> 18818917

Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.

Ashley M Groves1, Gordon C Wishart, Manu Shastry, Penelope Moyle, Sharon Iddles, Peter Britton, Mathew Gaskarth, Ruth M Warren, Peter J Ell, Kenneth A Miles.   

Abstract

PURPOSE: To assess the feasibility and first experience of combined (18)F-FDG-PET)/dynamic contrast-enhanced (DCE) CT in evaluating breast cancer.
METHODS: Nine consecutive female patients (mean age 64.2 years, range 52-74 years) with primary breast carcinoma were prospectively recruited for combined (18)F-FDG PET/DCE-CT. Dynamic CT data were used to calculate a range of parameters of tumour vascularity, and tumour (18)F-FDG uptake (standardized uptake value, SUVmax) was used as a metabolic indicator.
RESULTS: One tumour did not enhance and was excluded. The mean tumour SUVmax was 7.7 (range 2.4-26.1). The mean values for tumour perfusion, perfusion normalized to cardiac output, standard perfusion value (SPV) and permeability were 41 ml/min per 100 g (19-59 ml/min per 100 g), 0.56%/100 g (0.33-1.09%/100 g), 3.6 (2.5-5.9) and 0.15/min (0.09-0.30/min), respectively. Linear regression analysis showed a positive correlation between tumour SUV and tumour perfusion normalized to cardiac output (r=0.55, p=0.045) and a marginal correlation between tumour SUV and tumour SPV (r=0.19, p=0.065). There were no significant correlations between tumour SUV and tumour perfusion (r=0.29, p=0.401) or permeability (r=0.03, p=0.682).
CONCLUSION: The first data from combined (18)F-FDG-PET/DCE-CT in breast cancer are reported. The technique was successful in eight of nine patients. Breast tumour metabolic and vascular parameters were consistent with previous data from (15)O-H(2)O-PET.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818917     DOI: 10.1007/s00259-008-0948-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Measurement of tissue perfusion by dynamic computed tomography.

Authors:  K A Miles
Journal:  Br J Radiol       Date:  1991-05       Impact factor: 3.039

2.  CT measurements of capillary permeability within nodal masses: a potential technique for assessing the activity of lymphoma.

Authors:  K A Miles; B B Kelley
Journal:  Br J Radiol       Date:  1997-01       Impact factor: 3.039

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

5.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

6.  Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience.

Authors:  G Brix; M Henze; M V Knopp; R Lucht; J Doll; H Junkermann; H Hawighorst; U Haberkorn
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

7.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

9.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Impact of combined (18)F-FDG PET/CT in head and neck tumours.

Authors:  R Syed; J B Bomanji; N Nagabhushan; S Hughes; I Kayani; A Groves; S Gacinovic; N Hydes; D Visvikis; C Copland; P J Ell
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

View more
  19 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

2.  Combined PET/CT-perfusion in patients with head and neck cancers.

Authors:  Patrick Veit-Haibach; Daniel Schmid; Klaus Strobel; Jan D Soyka; Niklaus G Schaefer; Stephan K Haerle; Gerhard Huber; Gabriele Studer; Burkhardt Seifert; Thomas F Hany
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

3.  Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Savannah C Partridge; Risa K Vanantwerp; Robert K Doot; Xiaoyu Chai; Brenda F Kurland; Peter R Eby; Jennifer M Specht; Lisa K Dunnwald; Erin K Schubert; Constance D Lehman; David A Mankoff
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

Review 4.  Hybrid PET-dynamic CECT in the management of breast cancer.

Authors:  Rakesh Kumar; Chandan Jyoti Das
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.

Authors:  Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-24       Impact factor: 9.236

6.  Pretreatment PET in breast cancer: is there a role?

Authors:  Sue Chua; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 9.236

7.  PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.

Authors:  Paolo Orsaria; Agostino Chiaravalloti; Alessandro Fiorentini; Chiara Pistolese; Gianluca Vanni; Alessandra Vittoria Granai; Dimitrios Varvaras; Roberta Danieli; Orazio Schillaci; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

8.  Brain perfusion CT compared with ¹⁵O-H₂O PET in patients with primary brain tumours.

Authors:  Julie Marie Grüner; Rune Paamand; Michael Kosteljanetz; Helle Broholm; Liselotte Højgaard; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-27       Impact factor: 9.236

9.  Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients.

Authors:  Jill Rachel Mains; Frede Donskov; Erik Morre Pedersen; Hans Henrik Torp Madsen; Jesper Thygesen; Kennet Thorup; Finn Rasmussen
Journal:  Br J Radiol       Date:  2018-01-02       Impact factor: 3.039

10.  Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources.

Authors:  Charles R Meyer; Samuel G Armato; Charles P Fenimore; Geoffrey McLennan; Luc M Bidaut; Daniel P Barboriak; Marios A Gavrielides; Edward F Jackson; Michael F McNitt-Gray; Paul E Kinahan; Nicholas Petrick; Binsheng Zhao
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.